Background. In the randomized controlled Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), the efficacy of the 13-valent pneumococcal conjugate vaccine (PCV13) against first episodes of vaccine-type community-acquired pneumonia in adults aged ≥65 years was 46%. The long-term immunogenicity of PCV13 in pneumococcal vaccine-naive older adults was investigated as part of CAPiTA.
was introduced with better coverage against pneumococcal disease in all age groups. In adults 60-64 years of age, PCV13 was found to induce a greater functional immune response than the 23-valent PPV, suggesting that PCVs offer immunological advantages over PPVs for prevention of vaccine-type (VT) pneumococcal infection in adults [14] . It is unknown how long immune responses after PCV13 last, but a recent study in adults aged 50-59 years shows that antibody titers were maintained for at least 5 years postvaccination for 12 of the 13 vaccine serotypes [15] . In previous studies, no major differences in immunological responses to PCVs were observed between older adults suffering from common comorbidities such as diabetes mellitus or chronic lung disease as compared to healthy older adults [16] [17] [18] .
The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA), a randomized, double-blind clinical trial in 84 496 participants aged ≥65 years in the Netherlands, demonstrated the efficacy of PCV13 against first episodes of VT-CAP and first episodes of VT-IPD [18] . Within this study we have assessed the long-term immune responses to PCV13 compared with placebo up to 24 months postvaccination within a subset of 2011 vaccine-naive adults in different age and comorbidity groups.
METHODS
Immunogenicity data were collected as a substudy within CAPiTA. The study was a collaboration between University Medical Center Utrecht (UMCU) and the study sponsor, Wyeth, a Pfizer company. Study design and primary and secondary endpoints including safety data were previously published [18, 19] .
The study was conducted according to a written protocol and in compliance with Good Clinical Practice, and approved by the Central Committee on Research Involving Human Subjects and Ministry of Health, Welfare, and Sport in the Netherlands. The UMCU, Julius Clinical (an academic research organization affiliated with UMCU), and the Linnaeus Institute (a research organization of the Spaarne Hospital in Hoofddorp) conducted the immunogenicity substudy and gathered all data. The sponsor performed data management as well as immunogenicity and statistical analysis. Confidentiality agreements were in place between the sponsor, Spaarne Hospital, and UMCU, which allowed full access to all data and right to publish.
Study Design and Population
The study was a parallel-group, randomized, placebo-controlled, double-blind trial [19] . Use of a placebo was appropriate because no pneumococcal vaccine is recommended in the Netherlands for routine use in adults [19] [20] [21] . PPV23 is only advised in specific risk groups (eg, people suffering from asplenia, sickle-cell anemia, or liquor leakage after the age of 2 years), resulting in <1% of older adults having received PPV23 [19] [20] [21] . For infants, PCV7 was introduced in the national immunization program for children in June 2006 and was recommended for all infants born on or after 1 April 2006 as a 3 + 1 dose series at 2, 3, and 4 months of age with a booster at 11 months [22] without a catch-up campaign. In 2011, PCV7 was replaced by the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) for all infants born on or after 1 March 2011 at age 2, 4, and 11 months.
A subset of 2011 subjects was enrolled in a single region in the Netherlands for the immunogenicity substudy. Subjects were aged ≥65 years and enrolled between 15 September 2008 and 20 March 2009 at home visits. Eligibility criteria were no previous pneumococcal vaccination and immunocompetence evaluated by self-report. All subjects with immunocompromising conditions were excluded from the study. All subjects provided written informed consent. Full details of the eligibility criteria are provided in the Supplementary Materials.
Subjects were vaccinated at home visit 1 (baseline) and followed for 2 years through home visits to collect blood samples at baseline and at 1 month (day 29-43), 12 months, and 24 months postvaccination (Supplementary Figure 1) . All visits were performed by trained study personnel. Smoking status and comorbidities such as asthma, diabetes mellitus, heart disease, liver disease, lung disease, and splenectomy were reported by subjects at baseline and documented on a prespecified list (Supplementary Materials).
Investigational Products
Subjects were randomly assigned in a 1:1 ratio to receive PCV13 or placebo by intramuscular injection in the right deltoid. PCV13 contains capsular polysaccharides from pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F individually conjugated to a CRM 197 protein. The vaccine contains 2.2 μg of each polysaccharide, except for 4.4 μg of serotype 6B, with 5.0 mM succinate buffer, 0.85% sodium chloride, 0.02% polysorbate 80, and 0.125 mg aluminum as aluminum phosphate per 0.5-mL dose. The placebo contained 5.0 mM succinate buffer, 0.15 M sodium chloride, 0.02% polysorbate 80, and 0.125 mg aluminum as aluminum phosphate per 0.5-mL dose and was identical in appearance to PCV13.
Immunogenicity Analyses
Serum opsonophagocytic activity (OPA) titers for the 13 pneumococcal VTs were determined for all subjects and each blood sample to ascertain the concentration of functional anticapsular antibodies (antibody titer). This was done using a microcolony assay with a titer killing 50% of the bacteria in the assay as previously described [23] [24] [25] . OPA titers above the lower limit of quantitation (LLOQ) were considered accurate and their quantified values reported. OPA values below LLOQ were set to 0.5 × LLOQ for purposes of summary and analysis.
Enzyme-linked immunosorbent assay was used to determine the concentration of VT anticapsular pneumococcal binding immunoglobulin G (IgG), expressed as micrograms per milliliter as described elsewhere [26] [27] [28] . IgG values below the LLOQ were set to 0.5 × lower limit of detection (LOD) for purposes of summary and analysis.
Statistical Analyses
Within each vaccine group and for each serotype, OPA geometric mean antibody titers (GMTs) were calculated at all time points (baseline and 1, 12, and 24 months postvaccination) with 2-sided 95% confidence intervals (CIs). As post hoc analysis, the proportion of subjects achieving a ≥4-fold increase in OPA titer was assessed within each vaccine group and for each serotype. Although there is no consensus for a clinically meaningful, empirically predefined level of protection in adults, we considered subjects with OPA titers at baseline below LLOQ, but above LOD a responder when achieving a ≥4-fold increase in LLOQ. Subjects with OPA titers at baseline below LOD were considered a responder when achieving a ≥4-fold increase in LOD.
Similar analyses were done for IgG concentrations using geometric means of the IgG antibody concentrations (GMCs). For IgG, subjects achieving a ≥4-fold increase in IgG concentration with a minimal level of 1.00 μg/mL were considered responders. The minimum value of 1.00 mg/mL is a convenient cutoff that lies well above the 0.35 mg/mL used in children. It has not been tested in clinical studies.
Differences were considered significant if the nominal 95% CI excluded 0 for an endpoint of a difference between the compared groups (or 1 for an endpoint of a ratio of the compared groups) without adjusting for multiplicity due to multiple endpoints, time points, and comparisons.
RESULTS
Of the 2011 subjects enrolled in the immunogenicity substudy, 1006 received PCV13 and 1005 received placebo. Less than 3% (n = 56 [2.8%]) of the subjects were excluded from analyses, evenly divided over both groups ( Figure 1 ). The most common reason for exclusion was absence of a blood sample within the required time period. At each collection point, at least 93.4% of samples were collected within the required time period. Missing values were well balanced between the 2 groups. Discontinuation rates over the course of the study were 11.4% (n = 115) in PCV13 recipients and 12.1% (n = 122) in the placebo group. Discontinuation was mainly due to death (n = 142 [7.1%]).
Average age at vaccination was 72.5 years; 11.6% (n = 226) of the subjects were ≥80 years of age. Baseline characteristics as well as patient-reported comorbidities were well balanced between the 2 groups (Table 1) . Heart disease was the most commonly reported comorbidity (n = 444 [22.7%] ). There were no differences in age and comorbidity distribution between this subset and other subjects within CAPiTA [18] .
Opsonophagocytic Activity
Before vaccination, the OPA GMTs were similar in both groups ( Table 2 ). The OPA GMTs in the placebo group remained constant over time (Figure 2) . The OPA GMTs increased in PCV13 recipients 1 month postvaccination and decreased at 12 and 24 months after vaccination, but remained above baseline for all serotypes ( Table 2 ). The OPA GMTs of all 13 serotypes were statistically higher than baseline and the corresponding Opsonophagocytic activity values below the lower limit of quantitation (LLOQ) were set to 0. GMTs were calculated using all subjects with available data for the specified blood draw. c CIs are back-transformations of a CI based on the Student t distribution for the mean logarithm of the titers. GMFRs were calculated using all subjects with available data from both the before-vaccination and after-vaccination blood draws.
values in the placebo group at each postvaccination time point. The largest effects of PCV13 at 24 months postvaccination were observed for serotypes 4 and 18C (GMT >6-fold higher than baseline) and the smallest effects, for serotypes 3 and 9V (GMT <2-fold higher than baseline) ( Table 2 ). The decline in OPA GMTs was more pronounced in the first year than the second year postvaccination (Figure 2) .
The proportion of subjects who achieved a ≥4-fold increase in OPA titer 1 month postvaccination varied between 53.2% for serotype 14 to 86.5% for serotype 4 (Supplementary Table 1 ).
There was no difference between male and female subjects (data not shown).
Immunoglobulin G Antibodies
The IgG GMCs showed a similar pattern as the OPA GMTs (Table 3 ). IgG GMCs in the placebo group remained constant or decreased slightly (serotypes 3, 9V, 19A, 19F, and 23F), though not significantly. In PCV13 recipients, the IgG GMCs of all 13 serotypes increased after vaccination and declined after 1 month postvaccination. The largest difference at 24 months postvaccination was observed for serotypes 4 and 18C (GMC >4-fold higher than baseline) and the smallest for serotypes 3, 5, 6A, 6B, and 23F (GMC <2-fold higher than baseline). IgG GMCs in PCV13 recipients remained both above baseline and corresponding placebo levels for 2 years postvaccination, which was statically significant at each postvaccination time point.
In PCV13 recipients, the proportion of subjects reaching a ≥4-fold increase in IgG concentration with a minimal level of 1.00 μg/mL 1 month postvaccination varied between 32.7% for serotype 3 to 75.8% for serotype 4 (Supplementary Table 2 ).
Impact of Age
In the eldest PCV13 recipients (≥80 years of age at vaccination; n = 112 [11.4%]) postvaccination OPA GMTs were generally lower than in younger subjects, most obviously for serotypes 6A, 6B, 9V, 14, 18C, and 23F (Table 4 ). In addition, postvaccination fold increases in OPA GMTs in PCV13 recipients ≥80 years of age at vaccination were generally lower than in younger subjects, most obviously for serotypes 6B, 18C, 19A, and 23F (Table 4) . For serotype 14, there was a higher fold increase in PCV13 recipients ≥80 years of age at vaccination compared to younger age groups, though the resulting OPA at 12 and 24 months remained lower than in other age groups (Table 4) .
OPA GMTs of PCV13 recipients ≥80 years of age at vaccination remained above both baseline and the corresponding GMTs in the placebo group during the 2-year study period. The proportion of subjects achieving a ≥4-fold increase in OPA titer 1 month postvaccination appeared to be lower in PCV13 recipients ≥80 years of age at vaccination (Supplementary Table 3) . 10 100 1 000 1 0 000 100 000 10 00 000 1 0 1 00 1000 10 000 1 00 000 1 0 00000 10 100 1 000 1 0 000 100 000 10 00 000 1 0 1 00 1000 10 000 1 00 000 1 0 00000 10 100 1 000 1 0 000 100 000 10 00 000 1 0 1 00 1000 10 000 1 00 000 1 0 00000 10 100 1 000 1 0 000 100 000 10 00 000 1 0 1 00 1000 10 000 1 00 000 1 0 00000 IgG GMCs showed a similar pattern with lower GMCs for all serotypes in PCV13 recipients ≥80 years of age at vaccination compared to younger age groups, but remained above baseline and the corresponding GMCs in the placebo group at each postvaccination time point (Supplementary Table 4 ). Lower GMCs in PCV13 recipients ≥80 years of age at vaccination were especially seen in serotypes 1, 3, 6A, 6B, 18C, 19A, 19F, and 23F. There were no differences in fold increase (Supplementary  Table 4 ) or the proportion of subjects reaching a ≥4-fold increase in IgG concentration with a minimal level of 1.00 μg/ mL between the different age groups (Supplementary Table 5 ).
OPA GMT

Impact of Comorbidity
OPA GMTs in PCV13 recipients with 1 or more self-reported underlying medical conditions remained above baseline values at all postvaccination time points for each PCV13 serotype (Supplementary Table 6 ). Due to low numbers, effects of liver disease (n = 9 [0.5%]) and splenectomy (n = 2 [0.1%]) were not determined.
Overall, OPA and IgG responses as well as the proportion of subjects achieving a 4-fold increase in OPA or IgG levels following PCV13 were similar for subjects without any self-reported comorbidities and those with 1 or more underlying conditions (Supplementary Figure 2; Supplementary Tables 6-9 ).
DISCUSSION
A single dose of PCV13 in immunocompetent community-dwelling adults aged ≥65 years naive to pneumococcal vaccines elicited OPA GMTs and IgG GMCs that were significantly higher than baseline and the corresponding values in the placebo group at each postvaccination time point for 2 years after vaccination. In the eldest subjects (≥80 years at vaccination), postvaccination antibody levels remained well above baseline but were lower compared with younger age groups. Moreover, GMCs were calculated using all subjects with available data for the specified blood draw. c CIs are back-transformations of a CI based on the Student t distribution for the mean logarithm of the concentrations. GMFRs were calculated using all subjects with available data from both the before-vaccination and after-vaccination blood draws.
there was no apparent difference in immune responses to PCV13 between those with self-reported comorbidities and healthy older adults. However, this study was not powered to assess statistical differences among age and comorbidity subgroups.
To our knowledge, we are the first to report on the immunogenicity of PCV13 in a large placebo-controlled cohort of older adults in different age and comorbidity groups. Our findings are in line with results from smaller studies on the immunogenicity of PCV13 in older adults [11, 12, 16] and extend these observations [14] . We, however, also confirm that in older age groups, immune responses are generally lower than in younger age groups [29] [30] [31] [32] , though this was not corrected for the presence of comorbidities. Moreover, with respect to comorbidities, our data confirm that there are no apparent differences between healthy older adults and those with common comorbidities (excluding immunocompromising comorbidities) [33] .
Although there is no consensus for a clinically meaningful empirically predefined level of protection in adults, clinical data support functional antibody and OPA as the basis for protection [34] . Based upon the observed immunogenicity, it would be expected that the efficacy of PCV13 in older adults is not greatly influenced by increasing age or common comorbidities. Within CAPiTA, the efficacy of PCV13 appears to decrease with increasing age, but the study was not powered to demonstrate efficacy by age group [18] . The clinical impact of lower immune responses in adults ≥80 years of age at vaccination may also be confounded by other age-related factors and comorbidities.
In children, an IgG concentration of 0.35 μg/mL after the primary series of PCV is regarded as a correlate of protection against IPD [35] . However, as vaccine effectiveness differs per serotype, so does the expected serological level of protection [36] . In our study in older adults, IgG responses to serotype 3 are somewhat lower than responses to other serotypes. Effectiveness of PCV13 against serotype 3 IPD differs with recent studies reporting 79.5% in US children [37] and 68% and 44% in UK children and adults [9] , respectively. Nonetheless, vaccination with PCV13 in CAPiTA resulted in apparent clinical protection against serotype 3 CAP in older adults (PCV13 recipients: 7 CAP episodes by serotype 3; placebo group: 16 CAP episodes by serotype 3) [38] . However, CAPiTA was not powered to evaluate serotype-specific efficacy of PCV13.
PCVs elicit T cell-dependent immunological memory with the potential for recall response to natural exposure or revaccination. It remains unclear if PCVs indeed prolong the period of protection against VT pneumococcal disease compared to PPVs, especially in older adults in whom the ability to establish new memory responses is reduced due to a progressive loss of naive cells [16, 36] . Nonetheless, vaccine efficacy within CAPiTA was sustained throughout the trial duration (approximately 4-year mean follow-up) without evidence of waning efficacy [37] . Moreover, revaccination of adults 50-65 years of age with PCV13 after 4 years shows no hyporesponsiveness and induces greater OPA GMTs for half of the serotypes as compared to the first vaccination with PCV13 [9] . In healthy adults, circulating memory B-cell numbers 2 years postvaccination with PCV7 were better predicted by serotype-specific IgG concentrations before vaccination than by early postvaccination antibody responses [38] . For this reason, long-term immunogenicity data are needed to evaluate the mechanism and period of protection of a single dose of PCV13 in older adults and may depend more on biological age than chronological age [16] .
Caution is needed when interpreting the results of this study. First of all, the reported results on the effect of age and comorbidities are exploratory, as the study was not powered to assess any statistical differences between different age and comorbidity groups or individual serotypes. Furthermore, comorbidities were self-reported and only assessed at baseline.
CONCLUSIONS
A single dose of PCV13 elicits high titers of functional OPA and IgG antibodies during the first 2 years postvaccination in community-dwelling immunocompetent older adults aged ≥65 years naive to pneumococcal vaccines. Within the limitations of the study, adults aged ≥80 years at vaccination generally exhibited lower postvaccination antipneumococcal responses, but levels remained above baseline. There was no apparent difference in immune responses to PCV13 between those with self-reported comorbidities and healthy older adults. Longterm immunogenicity data are needed to evaluate the period of protection of a single dose of PCV13 in older adults.
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